Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MediPharm Labs ( (TSE:LABS) ) has provided an announcement.
MediPharm Labs, a specialized pharmaceutical cannabis company focused on precision-based cannabinoid ingredients and derived products for global medical markets, operates GMP-certified, ISO-standard facilities and has expanded its reach through regulatory approvals and strategic acquisitions. The company’s portfolio now spans extraction, formulation and distribution, as well as direct-to-patient platforms and medical clinics that deepen its presence in regulated cannabis therapeutics.
MediPharm Labs announced it will report full-year and fourth-quarter 2025 financial results before markets open on March 30, 2026, followed by a management-hosted conference call and webcast the same morning to discuss performance. The scheduled disclosure and investor events underscore the company’s effort to maintain transparency with shareholders as it advances its pharmaceutical-grade cannabis strategy and continues integrating its expanded medical patient platforms in Canada and abroad.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
Spark’s Take on LABS Stock
According to Spark, TipRanks’ AI Analyst, LABS is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics reflect ongoing losses, resulting in a lower score.
To see Spark’s full report on LABS stock, click here.
More about MediPharm Labs
MediPharm Labs is a pharmaceutical company focused on precision-based cannabinoids, specializing in purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. Operating from GMP-certified, ISO-standard facilities, it develops, formulates, processes, packages and distributes cannabinoid-based medicines to domestic and international medical markets, including Canada, Australia and Germany.
The company holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American firm with a commercial-scale domestic GMP license for extracting multiple natural cannabinoids, and it is pursuing foreign drug manufacturing site registration with the U.S. FDA. Its 2023 acquisition of VIVO Cannabis broadened access to medical patients via the Canna Farms ecommerce platform, Beacon Medical entities in Australia and Germany, and Harvest Medical Clinics in Canada, which provide physician consultations and prescriptions for medical cannabis.
Average Trading Volume: 155,989
Technical Sentiment Signal: Sell
Current Market Cap: C$29.45M
For a thorough assessment of LABS stock, go to TipRanks’ Stock Analysis page.